12.22

3.82% 0.45

After Hours: 12.11 -0.11 -0.90%

Helus Pharma Inc (HELP)

Overview News Price History Discussions Forecast

Helus Pharma Inc stock is traded at $12.22, with a volume of 1.02M. It is up +3.82% in the last 24 hours and up +31.68% over the past month. Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.

Previous Close:

$11.77

Open:

$11.81

24h Volume:

1.02M

Relative Volume:

0.70

Market Cap:

$892.80M

Revenue:

Net Income/Loss:

$-148.00M

P/E Ratio:

-2.7585

EPS:

-4.4299

Net Cash Flow:

$-135.66M

1W Performance:

+0.33%

1M Performance:

+31.68%

6M Performance:

+43.26%

1Y Performance:

+0.00%

1-Day Range:

$11.44

$12.26

1-Week Range:

$11.26

$12.26

52-Week Range:

$3.76

$14.35

Helus Pharma Inc Stock (HELP) Company Profile

Name

Helus Pharma Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

Address

Employee

Twitter

Next Earnings Date

2026-08-12

Latest SEC Filings

HELP's Discussions on Twitter

Compare HELP vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
HELP Helus Pharma Inc	12.22	911.06M	0	-148.00M	-135.66M	-4.4299
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Helus Pharma Inc Stock (HELP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-13-26	Initiated	TD Cowen	Buy
Feb-02-26	Initiated	Jefferies	Buy
Mar-13-25	Initiated	Guggenheim	Buy
Nov-19-21	Downgrade	Maxim Group	Buy → Hold

Helus Pharma Inc Stock (HELP) Latest News

Aug 21, 2026

Helus Pharma advances psychedelic treatments fo... - Pluang

Aug 21, 2026

Helus Pharma: An Undervalued Psychedelic Platform Approaching A Major Catalyst - Seeking Alpha

Aug 21, 2026

Cybin Stock Advances 5.23% as Phase 3 Depression Program, Leadership Expansion and Late-Stage Catalysts Lift Optimism - kalkine.ca

Aug 21, 2026

symbol__ Stock Quote Price and Forecast - CNN

Aug 21, 2026

Aug 20, 2026

HELP Stock Jumps 6% After TD Cowen Hikes Target Nearly 8x To $62 - Yahoo Finance

Aug 20, 2026

HELP Maintained by TD Cowen -- Price Target Raised to $62 - GuruFocus

Aug 20, 2026

TD Cowen raises Helus Pharma stock price target to $62 on trial timing - Investing.com Canada

Aug 20, 2026

Aug 19, 2026

Cybin (NYSE: HELP) plans 1.18M RSUs with first sale in 2026 - Stock Titan

Aug 19, 2026

Cybin Inc. (HELP) sets performance share plan through 2029 - Stock Titan

Aug 19, 2026

Helus Pharma stock rating reiterated at Buy by H.C. Wainwright - Investing.com Canada

Aug 19, 2026

Cybin (HELP) execs granted $12.6M shares as holders face 82% loss - Stock Titan

Aug 19, 2026

Aug 18, 2026

Helus Pharma Strengthens Leadership with Key Appointments as Pipeline Advances - citybuzz -

Aug 18, 2026

Cybin (HELP) adds exhibit to its base shelf registration - Stock Titan

Aug 18, 2026

How Helus’ new CEO plans to scale its psychedelic drug pipeline - Pharma Voice

Aug 18, 2026

Helus Pharma appoints former Intra-Cellular executives By Investing.com - Investing.com Canada

Aug 18, 2026

Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory BoardTue, 08/18/202607:30 - Helus Pharma

Aug 18, 2026

Aug 14, 2026